Abstract:Background: Poly(ADP-ribosyl)ation (PARylation) and SUMO modification (SUMOylation) are novel post-translational modifications (PTMs) mainly induced by PARP1 and SUMO1. Growing evidence has revealed that C/EBPβ plays multiple roles in biological processes and participates in cardiovascular diseases. However, the cross-talk between C/EBPβ PARylation and SUMOylation during pathological cardiac hypertrophy are not known.Methods: Abdominal aortic constriction (AAC) and phenylephrine (PE) were conducted to induce cardiac hypertrophy. Intramyocardial delivery of recombinant adenovirus (Ad-PARP1) was taken to induce PARP1 overexpression. Echocardiography, histological analysis, cell surface area and western blot were performed to detect cardiac function and hypertrophy. Co-Immunoprecipitation and immunofluorescence were conducted to test the relationship between C/EBPβ PARylation and SUMOylation.Findings: PARP1 positively regulate C/EBPβ PARylation and negatively regulate C/EBPβ SUMOylation. Moreover, the accumulation of PARylation of C/EBPβ at K134 site exhibits downregulation of C/EBPβ SUMOylation at the same site. In addition, C/EBPβ K134 site SUMOylation could decrease C/EBPβ protein stability and participates in PARP1-induced cardiac hypertrophy.Interpretation: These findings highlight the importance of the cross-talk between C/EBPβ PTMs at K134 site in determining its protein level and function, suggesting that multi-target therapeutic methods inhibiting PARP1 and activating C/EBPβ SUMOylation would be potential for treating pathological cardiac hypertrophy. Funding Information: National Natural Science Foundation of China (81872860, 81673433 and 81803521), Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program (2017BT01Y093), National Major Special Projects for the Creation and Manufacture of New Drugs (2019ZX09301104), China Postdoctoral Science Foundation (2019M652878).Declaration of Interests: The authors declare no competing interests.Ethics Approval Statement: All animal experiments in this study were approved by Research Ethics Committee of Sun Yat-sen University and conformed to Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised 1996).

The Cross-Talk&nbsp;Between PARylation and SUMOylation in C/EBPβ at K134 Site Participates in Pathological Cardiac Hypertrophy

The Cross-Talk Between PARylation and SUMOylation in C/EBPβ at K134 Site Participates in Pathological Cardiac Hypertrophy